Waratah Pharmaceuticals Inc.
Records under this name other than the patents Waratah Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 8 of 8 · Back to Waratah Pharmaceuticals Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,803,766 | Gastrin compositions and formulations, and methods of use and preparation Lapsed on the fee record Ended Sep 28, 2014 · USPTO record | Lapsed on the fee record | Ended Sep 28, 2014 | USPTO record |
| US 7,037,504 | Epidermal growth factor protein and gene, and methods of use therefor Lapsed on the fee record Ended May 2, 2014 · USPTO record | Lapsed on the fee record | Ended May 2, 2014 | USPTO record |
| US 6,288,301 | Treatment for juvenile diabetes Lapsed on the fee record Ended Sep 11, 2013 · USPTO record | Lapsed on the fee record | Ended Sep 11, 2013 | USPTO record |
| US 7,560,425 | Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes Lapsed on the fee record Ended Jul 14, 2013 · USPTO record | Lapsed on the fee record | Ended Jul 14, 2013 | USPTO record |
| US 7,476,388 | Composition comprising a gastrin/CCK receptor ligand and an EGF receptor ligand Lapsed on the fee record Ended Jan 13, 2013 · USPTO record | Lapsed on the fee record | Ended Jan 13, 2013 | USPTO record |
| US 6,558,952 | Treatment for diabetes Lapsed on the fee record Ended May 6, 2011 · USPTO record | Lapsed on the fee record | Ended May 6, 2011 | USPTO record |
| US 6,992,060 | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes Lapsed on the fee record Ended Jan 31, 2010 · USPTO record | Lapsed on the fee record | Ended Jan 31, 2010 | USPTO record |
| US 5,885,956 | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand Term ended Term ended no later than Mar 23, 2019 · Low confidence | Term ended | Term ended no later than Mar 23, 2019 | Low confidence |